Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 763

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 763
---
5. As a result of receiving the grant, the REM-001, 15-patientclinical trial was re-started.The grant is expended to the Company as a reimbursement of expenditures incurred. During the year ended June 30, 2024, the Company received $ 827(2023 - nil) for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

5. Property and equipment, net

| Balance, June 30, 2022 |     | $(thousands) |  90 |   |
|:-----------------------|:----|:-------------|----:|:--|
| Additions              |     |              | 679 |   |
| Less depreciation      |     |              | (60 | ) |
| Balance, June 30, 2023 |     |              | 709 |   |
| Additions              |     |              |  20 |   |
| Less depreciation      |     |              | (55 | ) |
| Balance, June 30, 2024 |     |              | 674 |   |

At June 30, 2024, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 499 is not in use. The Company has recognized $ 55 (2023 - $ 60 ) in depreciation expense for the year ended June 30, 2024, on equipment in use.

F-15

6. Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083owned by Valent. The Company now owns all rights and title to VAL-083and is responsible for further development and commercial